A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

Description

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Conditions

Cutaneous Sarcoidosis

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis

A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

Condition
Cutaneous Sarcoidosis
Intervention / Treatment

-

Contacts and Locations

San Francisco

Clinical Trial Site, San Francisco, California, United States, 94115

Durham

Clinical Trial Site, Durham, North Carolina, United States, 27703

Philadelphia

Clinical Trial Site, Philadelphia, Pennsylvania, United States, 19104

Madison

Clinical Trial Site, Madison, Wisconsin, United States, 53715

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adults subjects (18-74)
  • 2. Cutaneous sarcoidosis with characteristic skin biopsy histology
  • 3. A CSAMI activity score ≥ 10
  • 4. Weight \> 40 kg to \< 130 kg with BMI \< 40 kg/m2 .
  • 1. History of
  • * Lymphoproliferative disorder
  • * Active malignancy;
  • * History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix).
  • 2. High risk of thrombosis or cardiovascular disease
  • 3. High risk of herpes zoster
  • 4. Active or recent infection

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Priovant Therapeutics, Inc.,

Study Record Dates

2026-12